Immunotherapy advances最新文献_第6页

Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood. 免疫抑制耐药装甲T细胞对循环hbv相关HCC的全血溶解效率。

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad015

Meiyin Lin, Sebastian Chakrit Bhakdi, Damien Tan, Joycelyn Jie Xin Lee, David Wai Meng Tai, Andrea Pavesi, Lu-En Wai, Tina Wang, Antonio Bertoletti, Anthony Tanoto Tan

{"title":"Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood.","authors":"Meiyin Lin, Sebastian Chakrit Bhakdi, Damien Tan, Joycelyn Jie Xin Lee, David Wai Meng Tai, Andrea Pavesi, Lu-En Wai, Tina Wang, Antonio Bertoletti, Anthony Tanoto Tan","doi":"10.1093/immadv/ltad015","DOIUrl":"https://doi.org/10.1093/immadv/ltad015","url":null,"abstract":"Recurrence of hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) after liver transplant (LT) is mediated by circulating tumour cells (CTCs) and exacerbated by the immunosuppressants required to prevent graft rejection. To circumvent the effects of immunosuppressants, we developed immunosuppressive drug-resistant armoured HBV-specific T-cell receptor-redirected T cells (IDRA HBV-TCR). However, their ability to eliminate HBV-HCC circulating in the whole blood has never been tested, and whether their lytic efficacy is compatible with the number of adoptively transferred T cells in vivo has never been measured. Hence, we developed a microscopy-based assay to quantify CTCs in whole blood. The assay was then used to quantify the efficacy of IDRA HBV-TCRs to lyse free-floating HBV-HCC cells in the presence of Tacrolimus and Mycophenolate Mofetil (MMF). We demonstrated that a panel of antibodies (AFP, GPC3, Vimentin, pan-Cytokeratin, and CD45) specific for HCC tumour antigens and immune cells can effectively differentiate HCC-CTCs in whole blood. Through dose-titration experiments, we observed that in the presence of immunosuppressive drugs, a minimum of 20 000 IDRA HBV-TCR T cells/ml of whole blood is necessary to lyse ~63.5% of free-floating HBV-HCC cells within 16 hours. In conclusion, IDRA HBV-TCR T cells can lyse free-floating HBV-HCC cells in whole blood in the presence of Tacrolimus and MMF. The quantity of IDRA-HBV TCR T cells required can be achieved by the adoptive transfer of 5 × 106 IDRA-HBV TCR-T cells/kg, supporting the utilisation of IDRA HBV-TCR T cells to eliminate CTCs as prophylaxis against recurrence after LT.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"3 1","pages":"ltad015"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/10/ltad015.PMC10460197.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10109074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective. 基于treg的免疫疗法对抗原特异性免疫抑制和稳定耐受诱导的研究进展

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad007

Shimon Sakaguchi, Ryoji Kawakami, Norihisa Mikami

{"title":"Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective.","authors":"Shimon Sakaguchi, Ryoji Kawakami, Norihisa Mikami","doi":"10.1093/immadv/ltad007","DOIUrl":"https://doi.org/10.1093/immadv/ltad007","url":null,"abstract":"FoxP3-expressing regulatory T cells (Tregs), whether naturally generated in the immune system or unnaturally induced from conventional T cells (Tconvs) in the laboratory, have much therapeutic value in treating immunological diseases and establishing transplantation tolerance. Natural Tregs (nTregs) can be selectively expanded in vivo by administration of low-dose IL-2 or IL-2 muteins for immune suppression. For adoptive Treg cell therapy, nTregs can be expanded in vitro by strong antigenic stimulation in the presence of IL-2. Synthetic receptors such as CAR can be expressed in nTregs to equip them with a particular target specificity for suppression. In addition, antigen-specific Tconvs can be converted in vitro to functionally stable Treg-like cells by a combination of antigenic stimulation, FoxP3 induction, and establishment of the Treg-type epigenome. This review discusses current and prospective strategies for Treg-based immune suppression and the issues to be resolved for achieving stable antigen-specific immune suppression and tolerance induction in the clinic by targeting Tregs.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"3 1","pages":"ltad007"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/65/ltad007.PMC10309084.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10123148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TIGIT-based immunotherapeutics in lung cancer. 基于tigit的肺癌免疫治疗。

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad009

Akshay J Patel, Gary W Middleton

引用次数: 0

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. 更正:sabatolimab的特性，一种针对TIM-3受体具有免疫髓系活性的新型免疫疗法。

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad002

引用次数: 0

Correction to: Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity. 抗原特异性免疫治疗的进展:过敏和自身免疫之间的知识转移。

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad004

引用次数: 0

A historical perspective on HLA. HLA的历史观点。

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad014

Walter Bodmer

引用次数: 0

A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG⁺ hybridomas in comparison to its recombinant allergen-drug conjugate. 与重组的过敏原-药物偶联物相比，重组的Der 1特异性过敏原毒素对过敏原反应性IgG+杂交瘤的杀伤能力更强。

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltac023

A K Daramola, O A Akinrinmade, E A Fajemisin, K Naran, N Mthembu, S Hadebe, F Brombacher, A M Huysamen, O E Fadeyi, R Hunter, S Barth

{"title":"A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG+ hybridomas in comparison to its recombinant allergen-drug conjugate.","authors":"A K Daramola, O A Akinrinmade, E A Fajemisin, K Naran, N Mthembu, S Hadebe, F Brombacher, A M Huysamen, O E Fadeyi, R Hunter, S Barth","doi":"10.1093/immadv/ltac023","DOIUrl":"https://doi.org/10.1093/immadv/ltac023","url":null,"abstract":"Introduction: Current treatments for asthma help to alleviate clinical symptoms but do not cure the disease. In this study, we explored a novel therapeutic approach for the treatment of house dust mite allergen Der p 1induced asthma by aiming to eliminate specific population of B-cells involved in memory IgE response to Der p 1.Materials and methods: To achieve this aim, we developed and evaluated two different proDer p 1-based fusion proteins; an allergen-toxin (proDer p 1-ETA) and an allergen-drug conjugate (ADC) (proDer p 1-SNAP-AURIF) against Der p 1 reactive hybridomas as an in vitro model for Der p 1 reactive human B-cells. The strategy involved the use of proDer p 1 allergen as a cell-specific ligand to selectively deliver the bacterial protein toxin Pseudomonas exotoxin A (ETA) or the synthetic small molecule toxin Auristatin F (AURIF) into the cytosol of Der p 1 reactive cells for highly efficient cell killing.Results: As such, we demonstrated recombinant proDer p 1 fusion proteins were selectively bound by Der p 1 reactive hybridomas as well as primary IgG1+ B-cells from HDM-sensitized mice. The therapeutic potential of proDer p 1-ETA' and proDer p 1-SNAP-AURIF was confirmed by their selective cytotoxic activities on Der p 1 reactive hybridoma cells. The allergen-toxin demonstrated superior cytotoxic activity, with IC50 values in the single digit nanomolar value, compared to the ADC.Discussions: Altogether, the proof-of-concept experiments in this study provide a promising approach for the treatment of patients with house dust mite-driven allergic asthma.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"3 1","pages":"ltac023"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10738268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leveraging the lymphohematopoietic graft-versus-host reaction (LGVHR) to achieve allograft tolerance and restore self tolerance with minimal toxicity. 利用淋巴造血移植物抗宿主反应(LGVHR)实现同种异体移植物耐受并以最小的毒性恢复自身耐受。

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad008

Megan Sykes

引用次数: 0

Human Infection Challenge in the Pandemic Era and Beyond, HIC-Vac annual meeting report, 2022 大流行时代及以后的人类感染挑战，HIC-Vac年度会议报告，2022年

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad024

Megan V C Barnes, Anika Mandla, Emma Smith, Maija Maskuniitty, Peter J M Openshaw

{"title":"Human Infection Challenge in the Pandemic Era and Beyond, HIC-Vac annual meeting report, 2022","authors":"Megan V C Barnes, Anika Mandla, Emma Smith, Maija Maskuniitty, Peter J M Openshaw","doi":"10.1093/immadv/ltad024","DOIUrl":"https://doi.org/10.1093/immadv/ltad024","url":null,"abstract":"Summary HIC-Vac is an international network of researchers dedicated to developing human infection challenge studies to accelerate vaccine development against pathogens of high global impact. The HIC-Vac Annual Meeting (3rd and 4th November 2022) brought together stakeholders including researchers, ethicists, volunteers, policymakers, industry partners, and funders with a strong representation from low- and middle-income countries. The network enables sharing of research findings, especially in endemic regions. Discussions included pandemic preparedness and the role of human challenge to accelerate vaccine development during outbreak, with industry speakers emphasising the great utility of human challenge in vaccine development. Public consent, engagement, and participation in human challenge studies were addressed, along with the role of embedded social science and empirical studies to uncover social, ethical, and regulatory issues around human infection challenge studies. Study volunteers shared their experiences and motivations for participating in studies. This report summarises completed and ongoing human challenge studies across a variety of pathogens and demographics, and addresses other key issues discussed at the meeting.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135447286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment. 优化双特异性t细胞接合体在癌症治疗中的联合疗法。

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad013

Winston M Zhu, Mark R Middleton

引用次数: 1